HUB Organoids in Financial Times

December 10, 2019. Yesterday the Financial Times featured an article on Organoid Innovation:

Organoid innovation offers potential for cancer research.

“Organoids have become one of the fastest growing fields in biomedical research over the past decade”

Prof Clevers: “We set up a non-profit foundation called Hubrecht Organoid Technology [HUB], which holds my lab’s patents. In addition to carrying out research, HUB offers licences for drug screening and access to organoids in its biobanks for pre-clinical drug discovery and validation.”

Pharmaceutical companies are using organoids derived from specific tumours to screen potential cancer drugs. A wide range of tissues are available for applications ranging from drug discovery to personalised medicine.

December 10, 2019 HUB Organoids in Financial Times December 10, 2019. Yesterday the Financial Times featured an article on Organoid Innovation: Organoid innovation offers ... read more
October 18, 2019 CrownBio launched patient-derived tumor organ... San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development pl... read more
October 01, 2019 Hubrecht Organoid Technology and MIMETAS to d... Leiden, Utrecht September 2019 MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategi... read more